Aβ20-29 peptide blocking apoE/Aβ interaction reduces full-length Aβ42/40 fibril formation and cytotoxicity in vitro

Neuropeptides

Volumn 44, Issue 4, 2010, Pages 305-313

  Hao, Jian ^a   Zhang, Wei ^a   Zhang, Peng ^a   Liu, Rui ^a   Liu, Linna ^a   Lei, Gesheng ^a   Su, Changjun ^a   Miao, Jianting ^a   Li, Zhuyi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid beta protein; Apolipoprotein E; Cytotoxicity; Electron microscopy; Thioflavin T

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[20-29]; APOLIPOPROTEIN E; THIOFLAVINE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN (20 29); AMYLOID BETA-PROTEIN (20-29); FLUORESCENT DYE; PEPTIDE FRAGMENT; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ALZHEIMER DISEASE; ARTICLE; CELL STRAIN; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; ELECTRON MICROSCOPY; FIBER; FLUORESCENCE SPECTROSCOPY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; CELL CULTURE; CELL SURVIVAL; DRUG ANTAGONISM; HUMAN; METABOLISM; NEUROFILAMENT; PATHOLOGY; PHYSIOLOGY; SPECTROFLUOROMETRY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; CELL SURVIVAL; CELLS, CULTURED; FLUORESCENT DYES; HUMANS; MICROSCOPY, ELECTRON; NEUROFIBRILS; PEPTIDE FRAGMENTS; SPECTROMETRY, FLUORESCENCE; TETRAZOLIUM SALTS; THIAZOLES;

EID: 77953543564     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2010.03.001     Document Type: Article

References (59)

1. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V., Ghetti B., Paul S.M. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 1999, 96:15233-15238.
2. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., Piccardo P., Ghetti B., Paul S.M. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997, 17:263-264.
3. Baum L., Chen L., Ng H.K., Pang C.P. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology. Microsc. Res. Technol. 2000, 50:278-281.
4. Baumann M.H., Kallijärvi J., Lankinen H., Soto C., Haltia M. Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides. Biochem. J. 2000, 349:77-84.
5. Carter D.B. The interaction of amyloid-beta with ApoE. Subcell. Biochem. 2005, 38:255-272.
6. Carter D.B., Dunn E., McKinley D.D., Stratman N.C., Boyle T.P., Kuiper S.L., Oostveen J.A., Weaver R.J., Boller J.A., Gurney M.E. Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann. Neurol. 2001, 50:468-475.
7. Castano E.M., Prelli F., Wisniewski T., Golabek A., Kumar R.A., Soto C., Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 1995, 306:599-604.
8. Cedazo-Mínguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med. 2007, 11:1227-1238.
9. Dickson T.C., Saunders H.L., Vickers J.C. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. Neuropathol. Appl. Neurobiol. 1997, 23:483-491.
10. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., Holtzman D.M. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2002, 9:305-318.
11. Golabek A.A., Soto C., Vogel T., Wisniewski T. The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. J. Biol. Chem. 1996, 271:10602-10606.
12. Gorevic P.D., Castano E.M., Sarma R., Frangione B. Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X-ray diffraction pattern. Biochem. Biophys. Res. Commun. 1987, 147:854-862.
13. Hasegawa K., Yamaguchi I., Omata S., Gejyo F., Naiki H. Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1999, 38:15514-15521.
14. Holtzman D.M. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J. Mol. Neurosci. 2001, 17:147-155.
15. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2000, 97:2892-2897.
16. Irizarry M.C., Cheung B.S., Rebeck G.W., Paul S.M., Bales K.R., Hyman B.T. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta. Neuropathol. 2000, 100:451-458.
17. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
18. LaDu M.J., Falduto M.T., Manellim A.M., Reardon C.A., Getz G.S., Frail D.E. Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 1994, 269:23403-23406.
19. Lahiri D.K. Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. J. Mol. Neurosci. 2004, 23:225-233.
20. Liu R., Barkhordarian H., Emadi S., Park C.B., Sierks M.R. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol. Dis. 2005, 20:74-81.
21. Liu R., McAllister C., Lyubchenko Y., Sierks M.R. Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. J. Neurosci. Res. 2004, 75:162-171.
22. Ma J., Brewer H.B., Potter H. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Neurobiol. Aging 1996, 17:773-780.
23. Ma J., Yee A., Brewer H.B., Das S., Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994, 372:92-94.
24. Mantyh P.W., Ghilardi J.R., Rogers S., DeMaster E., Allen C.J., Stimson E.R., Maggio J.E. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J. Neurochem. 1993, 61:1171-1174.
25. McNamara M.J., Gomez-Isla T., Hyman B.T. Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch. Neurol. 1998, 55:1001-1004.
26. Miao J., Vitek M.P., Xu F., Previti M.L., Davis J., Van Nostrand W.E. Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J. Neurosci. 2005, 25:6271-6277.
27. Naiki H., Nakakuki K. First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab. Invest. 1996, 74:374-383.
28. Nakagami Y., Nishimura S., Murasugi T., Kaneko I., Meguro M., Marumoto S., Kogen H., Koyama K., Oda T. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br. J. Pharmacol. 2002, 137:676-682.
29. Näslund J., Thyberg J., Tjernberg L.O., Wernstedt C., Karlstrom A.R., Bogdanovic N., Gandy S.E., Lannfelt L., Terenius L., Nordstedt C. Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron 1995, 15:219-228.
30. Navarro A., Del Valle E., Astudillo A., González del Rey C., Tolivia J. Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral beta amyloid deposits. Exp. Neurol. 2003, 184:697-704.
31. Ono K., Hasegawa K., Yoshiike Y., Takashima A., Yamada M., Naiki H. Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J. Neurochem. 2002, 81:434-440.
32. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 1993, 13:1676-1687.
33. Pillot T., Goethals M., Najib J., Labeur C., Lins L., Chambaz J., Brasseur R., Vandekerckhove J., Rosseneu M. Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. J. Neurochem. 1999, 72:230-237.
34. Refolo L.M., Fillit H.M. Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease. J. Mol. Neurosci. 2004, 23:151-155.
35. Sadowski M., Pankiewicz J., Scholtzova H., Ripellino J.A., Li Y., Schmidt S.D., Mathews P.M., Fryer J.D., Holtzman D.M., Sigurdsson E.M., Wisniewski T. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am. J. Pathol. 2004, 165:937-948.
36. Sadowski M.J., Pankiewicz J., Scholtzova H., Mehta P.D., Prelli F., Quartermain D., Wisniewski T. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2006, 103:18787-18792.
37. Sanan D.A., Weisgraber K.H., Russell S.J., Mahley R.W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A.D. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 1994, 94:860-869.
38. Schenk D. Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course. Alzheimers Dement. 2008, 4:S119-121.
39. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000, 106:1489-1499.
40. Shimizu T., Fukuda H., Murayama S., Izumiyama N., Shirasawa T. Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. J. Neurosci. Res. 2002, 70:451-461.
41. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90:9649-9653.
42. Selkoe D.J. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell. Biol. 1994, 10:373-403.
43. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
44. St.George-Hyslop P.H., Petit A. Molecular biology and genetics of Alzheimer's disease. CR Biol. 2005, 328:119-130.
45. Stine W.B., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 2003, 278:11612-11622.
46. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90:8098-8102.
47. Sweeney D., Martins R., LeVine H., Smith J.D., Gandy S. Similar promotion of Abeta1-42 fibrillogenesis by native apolipoprotein E epsilon3 and epsilon4 isoforms. J. Neuroinflamm. 2004, 1:15.
48. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., Zlokovic B., Smith J.D., Ladu M.J., Rostagno A., Frangione B., Ghiso J. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J. 2000, 348:359-365.
49. Tomiyama T., Corder E.H., Mori H. Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer's disease. Cell. Mol. Life. Sci. 1999, 56:268-279.
50. van Marum R.J. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol. 2008, 22:265-274.
51. Wengenack T.M., Curran G.L., Poduslo J.F. Targeting Alzheimer amyloid plaques in vivo. Nat. Biotechnol. 2000, 18:868-872.
52. Wisniewski T., Castaño E.M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 1994, 145:1030-1035.
53. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 1992, 135:235-238.
54. Wisniewski T., Golabek A.A., Matsubara E., Ghiso J., Frangione B. Apolipoprotein E: binding to soluble Alzheimer's β-amyloid. Biochem. Biophys. Res. Commun. 1993, 192:359-365.
55. Wu B., Kitagawa K., Liu B., Zhang N.Y., Xiong Z.M., Inagaki C. Attenuation of amyloid beta (Abeta)-induced inhibition of phosphatidylinositol 4-kinase activity by Abeta fragments, Abeta20-29 and Abeta31-35. Neurosci. Lett. 2006, 396:148-152.
56. Yamaguchi H., Sugihara S., Ogawa A., Oshima N., Ihara Y. Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects. J. Neuropathol. Exp. Neurol. 2001, 60:731-739.
57. Yoshiike Y., Tanemura K., Murayama O., Akagi T., Murayama M., Sato S., Sun X., Tanaka N., Takashima A. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J. Biol. Chem. 2001, 276:32293-32299.
58. Zhou Z., Smith J.D., Greengard P., Gandy S. Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Mol. Med. 1996, 2:175-180.
59. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J. Neurochem. 2004, 89:807-811.